[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Wave Life Sciences Inc (WVE)

Wave Life Sciences Inc (WVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Wave Life Sciences Inc 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER SINGAPORE U0 018936 SGP

www.wavelifesciences.com Employees: 317 P: 65-6236-3388

Sector:

Medical

Description:

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.

Key Statistics

Overview:

Market Capitalization, $K 1,042,384
Enterprise Value, $K 448,184
Shares Outstanding, K 197,048
Float, K 149,165
% Float 75.70%
Short Interest, K 16,402
Short Float 8.32%
Days to Cover 7.45
Short Volume Ratio 0.27
% of Insider Shareholders 24.30%
% of Institutional Shareholders 89.73%

Financials:

Annual Sales, $ 42,730 K
Annual Net Income, $ -204,380 K
Last Quarter Sales, $ 2,270 K
Last Quarter Net Income, $ -69,360 K
EBIT, $ -217,920 K
EBITDA, $ -209,070 K

Growth:

1-Year Return -45.80%
3-Year Return 11.60%
5-Year Return -10.94%
5-Year Revenue Growth 112.80%
5-Year Earnings Growth 68.32%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.34 on 07/30/26
Next Earnings Date 11/09/26
Earnings Per Share ttm -1.09
EPS Growth vs. Prev Qtr -161.54%
EPS Growth vs. Prev Year -9.68%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

WVE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -50.36%
Return-on-Assets % -40.06%
Profit Margin % -478.31%
Debt/Equity 0.00
Price/Sales 24.21
Price/Cash Flow N/A
Price/Book 2.28
Book Value/Share 2.30
Interest Coverage -1.71
60-Month Beta -1.26
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.